GERD and Barrett's Esophagus

Mechanical/anatomic causes (barrier failure)

• Hiatal hernia: displaces the LES above the diaphragmatic crura, abolishing the crural "pinchcock" and the intra-abdominal segment of esophagus; the single most consistent anatomic association with erosive disease and long-segment Barrett's
• Increased intra-abdominal pressure: central obesity, pregnancy, ascites, and tight garments raise the gastroesophageal pressure gradient; pregnancy adds progesterone-mediated smooth-muscle relaxation
• Prior myotomy or gastric surgery: iatrogenic disruption of the sphincter complex (classically post-Heller myotomy reflux)

Motility and secretory causes

• Systemic sclerosis/CREST: smooth-muscle atrophy and fibrosis produce a hypotensive LES plus aperistaltic distal esophagus — severe reflux with poor clearance, a favorite stem for refractory GERD with strictures
• Gastroparesis (diabetic, post-vagotomy): delayed emptying increases refluxate volume
• Zollinger–Ellison syndrome: gastrin-driven acid hypersecretion causing refractory esophagitis and duodenal ulcers

Modifiable risk factors

• Obesity, especially visceral adiposity — the strongest modifiable driver of GERD, Barrett's, and adenocarcinoma; the ACG GERD guideline recommends weight loss as first-line
• Tobacco smoking: lowers LES pressure, reduces salivary bicarbonate, and independently increases adenocarcinoma risk
• Medications that relax the LES: nitrates, calcium channel blockers (especially dihydropyridines), anticholinergics, benzodiazepines, theophylline; pill esophagitis agents (doxycycline, bisphosphonates, potassium chloride, NSAIDs) injure mucosa directly and are a distractor for GERD
• Dietary/behavioral: alcohol, late large fatty meals, recumbency after eating

Non-modifiable risk factors for Barrett's/adenocarcinoma (ACG screening criteria)

• Chronic GERD ≥5 years plus additional risks: age >50, male sex, white race, central obesity, current or past smoking, and a first-degree relative with Barrett's or esophageal adenocarcinoma
• **Inverse association with *Helicobacter pylori***: atrophic gastritis reduces acid output, so H. pylori colonization is epidemiologically protective against Barrett's — eradication is not GERD therapy

• Defective lower esophageal sphincter (LES) function: Decreased LES pressure (normal >15 mmHg; pathologic <10 mmHg) and increased transient LES relaxations (TLESRs) triggered by gastric distension allow retrograde reflux of gastric contents; smoking, alcohol, anticholinergics, and calcium channel blockers worsen tone
• Impaired acid clearance mechanisms: Reduced esophageal peristalsis (particularly secondary peristalsis) and decreased saliva production diminish the esophagus's ability to neutralize refluxed acid; gravity and swallowing are critical clearance mechanisms
• Increased gastric acid production and delayed gastric emptying: High gastric pressure gradients and prolonged residence time of acidic chyme increase refluxate volume and potency; fatty foods and anticholinergics slow gastric emptying
• Mucosal injury cascade in Barrett's esophagus: Chronic acid and bile acid exposure triggers repeated cycles of injury and regeneration; increased cell proliferation, oxidative stress, and inflammation lead to aberrant wound healing with columnar epithelium (including gastric cardiac mucosa and intestinal metaplasia with goblet cells) replacing native squamous epithelium
• Molecular progression to dysplasia: Accumulation of genetic alterations (p53 mutations, loss of 17p, aneuploidy) and epigenetic changes (promoter methylation) drive progression from non-dysplastic Barrett's → low-grade dysplasia → high-grade dysplasia → adenocarcinoma; inflammatory cytokines (IL-6, TNF-α) and increased NF-κB signaling accelerate transformation

• Heartburn (pyrosis) — the cardinal symptom, described as substernal burning pain radiating upward, typically worse postprandially, when lying flat, or at night; often prompts self-medication with antacids
• Regurgitation — effortless return of gastric contents into the mouth or pharynx, sometimes occurring at night causing aspiration risk and nocturnal cough; patients may report acidic or bitter taste
• Dysphagia and odynophagia — particularly in severe or complicated GERD; dysphagia to solids suggests stricture formation, while dysphagia to liquids raises concern for malignancy or severe motor dysfunction
• Extraesophageal manifestations — chronic cough (often nocturnal and dry), laryngitis, hoarseness (from vocal cord irritation), asthma exacerbation, and dental erosion; these atypical presentations may delay GERD diagnosis
• Asymptomatic Barrett's esophagus — approximately 40-50% of patients with Barrett's have minimal reflux symptoms, making screening of asymptomatic populations a controversial topic; discovered incidentally on endoscopy performed for other indications
• Red flags requiring urgent evaluation: dysphagia, odynophagia, persistent vomiting, GI bleeding, anemia, unintentional weight loss, and new-onset symptoms in patients >60 years suggest complications or malignancy

• Clinical diagnosis — GERD is primarily a clinical diagnosis based on characteristic symptoms (heartburn ≥2 days/week or use of reflux medications ≥2 days/week); empiric PPI trial for 2-4 weeks with symptom resolution supports GERD diagnosis without further testing
• Upper endoscopy (EGD) — indicated for alarm features, failure of PPI therapy, surveillance of Barrett's esophagus, and diagnosis of complications; appears normal in 60% of GERD patients ("non-erosive GERD"), but essential for Barrett's detection and dysplasia grading; findings include erythema, erosions (LA grading A-D), strictures, and Barrett's segments ≥3 cm in length
• Barrett's esophagus diagnostic criteria: (1) columnar epithelium visible above the gastroesophageal junction on endoscopy, (2) histologic confirmation of intestinal metaplasia with goblet cells on biopsy (Prague criteria require location and extent documentation); at least 8 biopsies from four quadrants recommended even in short segments
• Ambulatory pH/impedance monitoring — reserved for diagnostic uncertainty or atypical presentations; assesses acid exposure time (normal <4%) and correlates symptoms with reflux events; not routinely needed if PPI therapy successful
• High-definition endoscopy with narrow-band imaging (NBI) — enhances visualization of Barrett's columnar epithelium (salmon pink) versus squamous epithelium (pale); improves detection of dysplasia but does not replace standard biopsies
• Biopsy protocol and surveillance: Seattle protocol (4-quadrant biopsies every 1-2 cm) for Barrett's detection; non-dysplastic Barrett's requires surveillance endoscopy every 3-5 years; low-grade dysplasia (LGD) requires confirmation by second pathologist and endoscopy in 3-6 months; high-grade dysplasia (HGD) mandates immediate intervention

First-line medical therapy

• Proton pump inhibitors (PPIs) — most effective acid-suppressive agents; standard-dose omeprazole 20 mg daily, lansoprazole 30 mg daily, or pantoprazole 40 mg daily for GERD symptom control; higher doses (40 mg daily or b.i.d.) for more severe disease or Barrett's management; typically continued long-term as maintenance therapy since GERD recurs in 80% upon discontinuation
• Lifestyle modifications — weight loss (even 10% reduction improves symptoms), elevation of head of bed 30°, avoidance of triggers (spicy/fatty foods, citrus, tomatoes, chocolate, caffeine, alcohol, smoking), eating smaller meals 2-3 hours before bed, and avoidance of NSAIDs and medications that relax LES

Second-line agents (if PPI monotherapy insufficient)

• H2-receptor antagonists — less effective than PPIs but useful for breakthrough symptoms or mild disease; famotidine 20 mg b.i.d. has better efficacy than others; not typically used as monotherapy for GERD
• Antacids and alginates — provide rapid but short-lived relief; sucralfate forms a protective barrier but poor evidence for GERD; useful as adjuncts only
• Baclofen — GABA-B agonist that reduces TLESRs; limited by neurologic side effects (dizziness, fatigue) but effective in refractory cases at 10-20 mg t.i.d.

Endoscopic and surgical options

• Endoscopic therapy for Barrett's with dysplasia: radiofrequency ablation (RFA) preferred for non-dysplastic or dysplastic Barrett's with surface irregularities; endoscopic mucosal resection (EMR) for visible nodularity/ulceration or HGD; RFA reduces HGD progression to cancer by ~80%; combined EMR + RFA offers best outcomes for advanced lesions
• Laparoscopic fundoplication — for selected patients with objective GERD, normal esophageal motility, and good PPI response who prefer surgical intervention; success rates 80-90% for symptom relief but ~50% develop postoperative dysphagia; reserved for young patients with decades of therapy ahead
• LINX device (magnetic sphincter augmentation) — newer option for PPI-responsive GERD with normal motility; acts as mechanical barrier to reflux; similar efficacy to fundoplication with potentially fewer side effects, though long-term data limited

Management of Barrett's esophagus without dysplasia

• Continue PPI therapy to control reflux symptoms, though evidence that PPI reduces dysplasia progression is weak; surveillance endoscopy every 3-5

Complications of reflux itself

• Erosive esophagitis: acid-peptic mucosal breaks graded LA A–D; severe (LA C/D) disease predicts stricture and Barrett's and warrants repeat endoscopy after healing per ACG to exclude underlying Barrett's
• Peptic stricture: fibrotic healing of chronic ulceration produces a smooth, tapered distal narrowing; signaled by progressive dysphagia to solids with paradoxical improvement of heartburn. Food bolus impaction with inability to handle secretions is an emergency requiring urgent endoscopic disimpaction
• Esophageal ulcer with hemorrhage: deep ulceration can erode into submucosal vessels — hematemesis, melena, or iron-deficiency anemia; hemodynamically significant bleeding is an emergency (resuscitation, IV PPI, urgent EGD)
• Barrett's esophagus → dysplasia → adenocarcinoma: intestinal metaplasia is the obligate precursor; weight loss, anorexia, or dysphagia in a known Barrett's patient signals malignant progression until proven otherwise
• Extraesophageal injury: aspiration pneumonitis/pneumonia, reflux-triggered asthma, posterior laryngitis, and dental enamel erosion from acid contact
• Esophageal rings/webs and Schatzki ring: intermittent solid-food dysphagia; distinguish from eosinophilic esophagitis, which causes ringed "trachealized" esophagus with eosinophil-predominant biopsies

Complications of treatment

• Proton pump inhibitors: hypochlorhydria-related risks include Clostridioides difficile and enteric infections, community-acquired pneumonia, hypomagnesemia (may present with tetany or refractory hypokalemia), B12 and iron malabsorption, acute interstitial nephritis (fever, rash, eosinophilia, rising creatinine), fundic gland polyps, and rebound acid hypersecretion on abrupt withdrawal. Most are association-level data; ACG advises using the lowest effective dose rather than withholding indicated therapy
• Fundoplication: gas-bloat syndrome, inability to belch or vomit, postoperative dysphagia from an overly tight wrap, and vagal injury causing gastroparesis; wrap herniation or slippage recreates reflux
• Endoscopic ablation/EMR: post-procedure stricture, bleeding, and perforation — the last is an emergency presenting with chest pain, subcutaneous emphysema, and mediastinal air

• Goblet cells are the diagnosis: endoscopic salmon-colored mucosa extending above the gastroesophageal junction is only suggestive — Barrett's requires intestinal metaplasia with goblet cells on biopsy. A stem describing columnar mucosa without goblet cells is not Barrett's
• Alarm features change the next step: dysphagia, odynophagia, GI bleeding, anemia, vomiting, or unintentional weight loss means upper endoscopy first, not an empiric PPI trial (ACG). Barium swallow is a distractor and is not a diagnostic test for GERD
• Exclude cardiac disease before calling substernal chest pain reflux: in an adult with risk factors, ECG and troponin precede any GI workup; "GERD" is a diagnosis of exclusion in the ED
• Adenocarcinoma vs squamous cell carcinoma: adenocarcinoma arises in the distal third from Barrett's, linked to GERD, obesity, and smoking; squamous cell carcinoma arises in the middle third, linked to alcohol, smoking, achalasia, caustic injury, and hot beverages. This pairing is the most frequently tested association
• PPI therapy does not replace surveillance: acid suppression controls symptoms and heals esophagitis but has not been shown to abolish neoplastic progression — non-dysplastic Barrett's still needs interval endoscopy per ACG, and dysplasia is managed with endoscopic eradication, not more PPI
• High-grade dysplasia is treated, not watched: endoscopic mucosal resection of visible nodules followed by radiofrequency ablation is preferred over esophagectomy for confined disease; "repeat EGD in 3 years" is the trap answer
• Refractory heartburn with sclerodactyly, Raynaud, and telangiectasias = systemic sclerosis with an aperistaltic esophagus; manometry shows absent distal peristalsis and a hypotensive LES, and fundoplication is generally avoided because poor motility predicts dysphagia
• Test pH monitoring off PPI when confirming unproven GERD; performing it on therapy answers a different question and is a common distractor